Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Transnasal delivery of the peptide to the brain
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-B-111-Tuesday
- By: TANAKA, Akiko (Kyoto, Japan)
- Co-author(s): Akiko Tanaka: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Chiaki Maeda: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Mayumi Amano: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Kentaro Takayama: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Yoshio Hayashi: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Daisuke Inoue: School of Pharmacy, Shujitsu University, Okayama, Japan
Tomoyuki Furubayashi: School of Pharmacy, Shujitsu University, Okayama, Japan
Kosuke Kusamori: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Hidemasa Katsumi: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Toshiyasu Sakane: Department of Pharmaceutical Technology, Kobe Pharmaceutical University, Kobe, Japan;Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Akira Yamamoto: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan - Abstract:
Backgrounds
The obesity and the metabolic syndrome have prevailed all over the world. Recently, CPN-116 (CPN), which is a specific agonist peptide to neuromedin U receptor 2 (NMUR2), has been developed as a new therapeutic candidate for the treatments of obesity. The treatment with CPN will be unlikely successful due to the limited delivery to the.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023